Buprenorphine inhibits bradykinin-induced release of calcitonin gene-related peptide from rat trigeminal neurons via both μ-opioid and nociceptin/orphanin peptide receptors

In this study we used the dual opioid and nociceptin/orphanin peptide (NOP) agonist buprenorphine to investigate the relative contributions of opioid and NOP systems in regulating bradykinin-stimulated calcitonin-gene related peptide (CGRP) release from primary cultures of neonatal rat trigeminal ne...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2009-05, Vol.609 (1), p.45-50
Main Authors: Capuano, Alessandro, De Corato, Alice, Tringali, Giuseppe, Currò, Diego, Dello Russo, Cinzia, Navarra, Pierluigi
Format: Article
Language:English
Subjects:
Analgesics, Opioid - pharmacology
Animals
Biological and medical sciences
Bradykinin
Bradykinin - pharmacology
Buprenorphine
Buprenorphine - pharmacology
Calcitonin gene-related peptide
Calcitonin Gene-Related Peptide - metabolism
Cells, Cultured
Medical sciences
Neurons - drug effects
Nociceptin Receptor
NOP receptor
Pharmacology. Drug treatments
Rat trigeminal neuron
Rats
Rats, Wistar
Receptors, Opioid - physiology
Receptors, Opioid, mu - physiology
Trigeminal Nerve - cytology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study we used the dual opioid and nociceptin/orphanin peptide (NOP) agonist buprenorphine to investigate the relative contributions of opioid and NOP systems in regulating bradykinin-stimulated calcitonin-gene related peptide (CGRP) release from primary cultures of neonatal rat trigeminal neurons. We found that: bradykinin stimulates CGRP secretion either by a direct effect or after applying so-called “bradykinin -priming” protocol. In both cases, buprenorphine was able to inhibit bradykinin-stimulated CGRP secretion; however, inhibition was mediated by NOP receptors when buprenorphine was added to the incubation medium along with bradykinin, whereas it appeared to be mediated by μ-opioid receptors in bradykinin priming experiments. Bradykinin treatments also caused an increase in neuronal prostaglandin production; prostanoids appeared to be involved in the stimulatory effects of bradykinin as well as in buprenorphine inhibition, through apparently unrelated mechanisms.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2009.03.013